A high-level resignation inside the Department of Health and Human Services is now shedding new light on internal disagreements over vaping policy, as concerns mount about the potential impact on children and public health.
Rich Danker, chief spokesperson for HHS Secretary Robert F. Kennedy Jr., stepped down from his role as assistant secretary for public affairs on Wednesday, citing what he described as irreconcilable differences over efforts to advance flavored e-cigarette products. His departure came just one day after Marty Makary resigned from his position as commissioner of the Food and Drug Administration over the same issue.
In a resignation letter addressed to Donald Trump, Danker raised alarm about what he characterized as a push within senior HHS leadership to secure FDA approval for cigarette flavors that could appeal to children. He warned that such products risk exposing young people to nicotine addiction, lung damage, and an increased likelihood of cancer.
Danker also argued that approving these products on a routine basis would conflict with existing federal guidance. Specifically, he pointed to the FDA’s Flavored Electronic Nicotine Delivery Systems Premarket Applications Considerations Related to Youth Risk guidance issued in March, which had been supported by the White House. According to Danker, advancing flavored products would undermine those standards.
Despite his strong objections, Danker did not place blame on President Trump personally, even as the administration has taken a clear stance in favor of preserving access to vaping products. The issue reflects a broader tension between regulatory caution and policy efforts aimed at maintaining consumer choice—an ongoing debate that continues to divide policymakers.
The controversy intensified last week when the administration approved the sale of several flavored nicotine vaping products, including blueberry- and mango-flavored pods, as well as two menthol options. The decision marked the first time a fruit-flavored electronic cigarette has been authorized for sale in the United States.
The products are set to be manufactured by Glas Inc., which has stated it will implement safeguards designed to prevent underage purchases. These measures include verifying government-issued identification and using Bluetooth-based smartphone checks to confirm a user’s age. Whether such safeguards will prove effective remains a point of concern for critics.
Danker’s resignation is not the first tied to internal disputes over health policy at HHS. In March 2025, then-top spokesperson Tom Corry also stepped down, citing disagreements with the department’s handling of a measles outbreak in Texas. The pattern of departures suggests deeper divisions within the agency at a time when public health decisions carry significant political and social consequences.
HHS did not immediately respond to requests for comment regarding Danker’s resignation.
The episode underscores a recurring challenge in Washington: balancing policy priorities with long-term consequences, particularly when it comes to issues affecting younger generations. While debates over regulation and personal freedom are nothing new, the stakes here involve public health risks that can echo far beyond the immediate policy fight.
As with other high-profile disputes inside government, the situation reveals how internal conflicts—much like broader political battles—can escalate quickly, leaving little room for consensus. And while the debate over vaping may seem far removed from larger geopolitical concerns, it reflects the same underlying dynamic: decisions made in the heat of political pressure can carry consequences that outlast the moment.
[READ MORE: Trump Taps ICE Veteran for Acting Role as Leadership Turnover Continues]
